Evidence mapPaperPMID 39289178Full record

ArticleJournal of chemical information and modeling2024

In Silico Insights: QSAR Modeling of TBK1 Kinase Inhibitors for Enhanced Drug Discovery.

Julian M Ivanov, Rumiana Tenchov, Krittika Ralhan, Kavita A Iyer, Shivangi Agarwal, Qiongqiong Angela Zhou

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Advancing drug development with "Fit-for-Purpose" modeling informed approaches.Journal of pharmacokinetics and pharmacodynamics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julian M IvanovCAS, A Division of the American Chemical Society, Columbus, Ohio 43210, United States.ORCID 0000-0002-3519-359X
Rumiana TenchovCAS, A Division of the American Chemical Society, Columbus, Ohio 43210, United States.ORCID 0000-0003-4698-6832
Krittika RalhanACS International India Pvt. Ltd., Pune 411044, India.
Kavita A IyerACS International India Pvt. Ltd., Pune 411044, India.
Shivangi AgarwalACS International India Pvt. Ltd., Pune 411044, India.
Qiongqiong Angela ZhouCAS, A Division of the American Chemical Society, Columbus, Ohio 43210, United States.ORCID 0000-0001-6711-369X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TBK1, or TANK-binding kinase 1, is an enzyme that functions as a serine/threonine protein kinase. It plays a crucial role in various cellular processes, including the innate immune response to viruses, cell proliferation, apoptosis, autophagy, and antitumor immunity. Dysregulation of TBK1 activity can lead to autoimmune diseases, neurodegenerative disorders, and cancer. Due to its central role in these critical pathways, TBK1 is a significant focus of research for therapeutic drug development. In this paper, we explore data from the CAS Content Collection regarding TBK1 and its implication in a large assortment of diseases and disorders. With the demand for developing efficient TBK1 inhibitors being outlined, we focus on utilizing a machine learning approach for developing predictive models for TBK1 inhibition, derived from the fragment-functional analysis descriptors. Using the extensive CAS Content Collection, we assembled a training set of TBK1 inhibitors with experimentally measured IC50 values. We explored several machine learning techniques combined with various molecular descriptors to derive and select the best TBK1 inhibitor QSAR models. Certain significant structural alerts that potentially contribute to inhibition of TBK1 are outlined and discussed. The merit of the article stems from identifying the most adequate TBK1 QSAR models and subsequent successful development of advanced positive training data to facilitate and enhance drug discovery for an important therapeutic target such as TBK1 inhibitors, based on an extensive, wide-ranging set of scientific information provided by the CAS Content Collection.

Indexed as

Drug DiscoveryMachine LearningProtein Kinase InhibitorsProtein Serine-Threonine KinasesQuantitative Structure-Activity RelationshipComputer SimulationHumansModels, MolecularProtein Kinase InhibitorsProtein Serine-Threonine KinasesTBK1 protein, human

Identifiers

PMID39289178
PMCPMC11480986

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.